Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
about
The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancerManaging the adverse events of intravesical bacillus Calmette-Guérin therapyBacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literatureDisseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder.Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancerGranulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guérin therapy: Case report.Could hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study.Immunotherapy for bladder cancer.Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin TherapyUse of bacille Calmette-Guérin in superficial bladder cancer.Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.BCG-induced pneumonitis with lymphocytic pleurisy in the absence of elevated KL-6Is bladder tumor location associated with prostate cancer detection after intravesical bacillus Calmette-Guérin instillation?Best practice in the treatment of nonmuscle invasive bladder cancer.Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancerImmunotherapy of genitourinary malignancies.Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?A Case of Acquired Rifampin Resistance in Mycobacterium Bovis Bacillus Calmette-Guérin-induced Cystitis: Necessity for Treatment GuidelinesBilateral symmetrical corneal melting following intravesical Bacille Calmette-Guerin therapy for bladder carcinoma.Myobacterium bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinomaInfected Aortic Aneurysm caused by Mycobacterium bovis after Intravesical Bacillus Calmette-Guérin Treatment for Bladder CancerPCR identification of Mycobacterium bovis BCGGranulomatous Prostatitis After Intravesical Bacillus Calmette-Guérin Instillation Therapy: A Potential Cause of Incidental F-18 FDG Uptake in the Prostate Gland on F-18 FDG PET/CT in Patients with Bladder CancerMycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells.Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer.Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective compaSystemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer.Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer.Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature.Bone and joint tuberculosis."BCGitis": A rare case of tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guérin therapy.Post-intravesical BCG epididymo-orchitis: Case report and a review of the literature.Complications of intravesical bacillus calmette-guérin.Bacillus Calmette-Guérin therapy-associated granulomatous prostatitis mimicking prostate cancer on MRI: A case report and literature review.
P2860
Q26770422-2AAD3044-49AE-46B6-9A4B-C51FFDA079B3Q26775644-F5823B2E-BE78-416F-95F5-1D5F0B1EF28AQ27021357-C9717D7D-4C35-4C73-9571-4BF910766CF4Q33167629-3198D2E8-B9BA-4094-91D2-F43CDDC01383Q33625843-62E15C13-BC11-4832-8720-FA54A095403EQ33780044-DD022104-99AF-4244-A614-3945CCAA841DQ34036190-16643095-1E5D-4A69-AC15-BDAB57B646FAQ34063277-D4AFF5C3-414F-44CC-A7D9-B243441914DBQ34477444-8A850BFF-EA94-4A58-897B-2A78D4978DC0Q34682234-D522A422-5E80-4AB7-A4A4-DD0414525044Q34788204-53CB65A9-DFA4-4B1C-ADD1-377EF0FDBC51Q35067132-DB50EDFE-A32A-44FB-9C34-92DABB32ADCBQ35110159-A86E2074-1891-4858-A87A-F72464F48E0AQ35214821-3EBFEC62-BBFA-42E8-89C5-45160586D2FFQ35688392-662D1FA2-3FCE-48C0-95A4-F08A93FC3310Q35690511-422DE394-390C-4B2B-BC83-0CB92140BAADQ35865051-282A6B92-3029-4151-8583-C0C513BF3B27Q36167778-999DD09E-593E-4B0B-9133-937527567397Q36171212-69BD34D7-4E59-402F-BBC7-026E9503FA6EQ36231443-2B8B1EB3-82C1-401D-ADF8-2D10CB4D3562Q36276438-EB5020BE-7C99-4B20-94AF-F45397268DB2Q36472378-5939473E-5448-4D5F-8ED9-766122F1BCB2Q36543379-7639E2C5-034B-471B-8868-9F5E7A7A7B7CQ36605018-E2D6AE62-A516-4287-9FD1-316E19016349Q36617339-0CC77252-7A32-40FD-878E-089B732AF5B7Q36777144-EFA967E6-1A81-429F-AA2C-4FF0CCEB5A7CQ36813770-39D6B962-1E89-486C-A0D7-790C75D1A6AFQ36939977-B7F2A6E2-1492-4108-91E9-0DBE703F753CQ37166445-5256204F-C5D7-41D9-9F51-C5304FDB133FQ37197530-C3220C95-1232-49AB-BDEC-C95477F293F0Q37317249-C05DF6EC-C00D-4239-BC9D-B59E09AA5DE5Q37352975-13A6E305-7F52-4572-8152-F957F99505BDQ37457553-21666112-9A95-41F1-9001-DB9F4D25BA69Q37589142-8486E238-AB6E-4AFD-A99E-3FC815251D6FQ37633934-A080BD74-0EE6-40BD-860C-56788BE7953FQ38019813-979736B2-B753-4540-ADB3-CB5F917CB1DBQ38078365-61DA3C9D-5E49-4B7D-B1A6-B42D865DC88CQ38121665-F3141FD8-C8C0-44FB-9D37-B7C2D225BEA9Q38248289-4C4166B2-A1E9-49D8-A499-78C45F328349Q38282107-4554DB75-C2E4-4FA0-9A9D-E349D525CF40
P2860
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Incidence and treatment of com ...... in superficial bladder cancer.
@en
type
label
Incidence and treatment of com ...... in superficial bladder cancer.
@en
prefLabel
Incidence and treatment of com ...... in superficial bladder cancer.
@en
P2093
P1476
Incidence and treatment of com ...... in superficial bladder cancer
@en
P2093
F M Debruyne
M S Soloway
P M van der Meijden
S A Brosman
W J Catalona
P304
P356
10.1016/S0022-5347(17)37316-0
P407
P577
1992-03-01T00:00:00Z